Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

By admin
This was originally published on post
WARREN, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (Nasdaq: MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft’s extensive